NoamKopmarMD

Physician

Dr. Kopmar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1959 Ne Pacific St
Room Bb-527
Seattle, WA 98195
Phone+1 206-543-3605

PubMed

2 citations
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10
Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs).
Emily C Liang, Jennifer J Huang, Andrew J Portuguese, Valentín Ortiz-Maldonado, Aya Albittar
Blood Advances. 2024-12-03
1 citations
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker
Journal of Clinical Oncology. 2024-10-17

Fred Hutch at ASCO: New Insights on Financial Toxicity, Combination Therapies for Cancer and the Need for Targeted Breast Cancer Therapies in UgandaMay 26th, 2023
‘Exciting’ Research Spotlights CAR-t’s Evolving Role in Blood Cancer TreatmentFebruary 22nd, 2023
Fred Hutch Experts Highlight Research on Cancer Treatment Advances, Survivorship and Precision Oncology at ASCOJune 6th, 2023